Table 5. Serial Determinations of i-DPD... | American Society of Hematology

Table 5.

Serial Determinations of i-DPD in Myeloma Patients Receiving Chemotherapy

Patient Stratification^5-150	No. of Patients	Baseline i-DPD		Follow-up i-DPD		Time Between Baseline and Follow-up Measurement (mo)		Significance of Changes in i-DPD
		(μmol/mol)		(μmol/mol)		Median	Range
		Median	Range	Median	Range
>25% decrease in the monoclonal protein	10^5-151	10.9	5.7-170.7	6.5	2.38-21	5	1-10	P = .0371
≤25% decrease or increase in the monoclonal protein	10	8.9	6.67-122.5	9.8	3.0-59.3	6	1-17	NS

Patient Stratification^5-150	No. of Patients	Baseline i-DPD		Follow-up i-DPD		Time Between Baseline and Follow-up Measurement (mo)		Significance of Changes in i-DPD
		(μmol/mol)		(μmol/mol)		Median	Range
		Median	Range	Median	Range
>25% decrease in the monoclonal protein	10^5-151	10.9	5.7-170.7	6.5	2.38-21	5	1-10	P = .0371
≤25% decrease or increase in the monoclonal protein	10	8.9	6.67-122.5	9.8	3.0-59.3	6	1-17	NS

Patients were stratified according to the level of the monoclonal protein at the time of i-DPD measurement.

None of the patients achieved complete remission (monoclonal protein undetectable by immunofixation).